Advertisement

Treatment of Anabolic-Androgenic Steroid Related Disorders

  • Harrison G. PopeJr.Email author
  • Gen Kanayama
Reference work entry

Abstract

The family of anabolic-androgenic steroids (AAS) comprises the male hormone testosterone and its many synthetic relatives. Although elite athletes have used AAS for muscle and performance gains since the 1950s, widespread AAS use did not emerge into the general population until the 1980s. Thus, AAS abuse is the youngest of the world’s major forms of substance abuse, with most AAS users still below age 50. There are now some tens of millions of AAS users worldwide, primarily male and primarily in Western societies. Contrary to common belief, most AAS users do not engage in competitive athletics, but simply want to become leaner and more muscular. AAS users may occasionally experience serious psychiatric effects, including hypomania or mania during AAS exposure and depression during AAS withdrawal. Long-term medical effects include especially cardiomyopathy, atherosclerotic disease, and prolonged suppression of the hypothalamic-pituitary-gonadal axis. About 30 % of AAS users develop dependence syndromes, likely caused by a confluence of psychosocial factors (e.g., using AAS to “self-treat” muscle dysmorphia), neuroendocrine factors (e.g., repeatedly resuming AAS use to self-treat hypogonadism during AAS withdrawal), and hedonic effects. A hedonic component is supported by evidence that male hamsters will self-administer testosterone to the point of death. Treatment of AAS dependence remains largely empirical, in part because most AAS abusers are still too young to have developed adverse effects. Thus, few have desired or sought treatment. This situation may change in future decades, however, as growing numbers of aging AAS users enter the age of risk for long-term adverse effects.

Keywords

Human Growth Hormone Manic Syndrome Classical Drug Abuse Body Dysmorphic Disorder Dependence Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Brennan BP, Kanayama G, Pope HG (2013) Performance-enhancing drugs on the web: a growing public-health issue. Am J Addict 22:158–161PubMedCentralPubMedCrossRefGoogle Scholar
  2. Brower KJ (2009) Anabolic steroid abuse and dependence in clinical practice. Phys Sportsmed 37:1–11CrossRefGoogle Scholar
  3. de Souza GL, Hallak J (2011) Anabolic steroids and male infertility: a comprehensive review. BJU Int 108:1860–1865PubMedCrossRefGoogle Scholar
  4. Dickerman RD, Pertusi RM, Zachariah NY et al (1999) Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 9:34–39PubMedCrossRefGoogle Scholar
  5. Dodge T, Hoagland MF (2011) The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend 114:100–109PubMedCentralPubMedGoogle Scholar
  6. Garevik N, Rane A (2010) Dual use of anabolic-androgenic steroids and narcotics in Sweden. Drug Alcohol Depend 109:144–146PubMedCrossRefGoogle Scholar
  7. Hall RC, Hall RC, Chapman MJ (2005) Psychiatric complications of anabolic steroid abuse. Psychosomatics 46:285–290PubMedCrossRefGoogle Scholar
  8. Hildebrandt T, Lai JK, Langenbucher JW et al (2011) The diagnostic dilemma of pathological appearance and performance enhancing drug use. Drug Alcohol Depend 114:1–11PubMedCentralPubMedCrossRefGoogle Scholar
  9. Ip EJ, Barnett MJ, Tenerowicz MJ et al (2011) The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy 31:757–766PubMedCrossRefGoogle Scholar
  10. Kanayama G, Pope HG (2012) Illicit use of androgens and other hormones: recent advances. Curr Opin Endocrinol Diabetes Obes 19:211–219PubMedCentralPubMedCrossRefGoogle Scholar
  11. Kanayama G, Hudson JI, Pope HG (2008) Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend 98:1–12PubMedCentralPubMedCrossRefGoogle Scholar
  12. Kanayama G, Brower KJ, Wood RI et al (2009) Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 104:1966–1978PubMedCentralPubMedCrossRefGoogle Scholar
  13. Kanayama G, Brower KJ, Wood RI et al (2010a) Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend 109:6–13PubMedCentralPubMedCrossRefGoogle Scholar
  14. Kanayama G, Hudson JI, Pope HG (2010b) Illicit anabolic-androgenic steroid use. Horm Behav 58:111–121PubMedCentralPubMedCrossRefGoogle Scholar
  15. Kanayama G, Boynes M, Hudson JI et al (2007) Anabolic steroid abuse among teenage girls: an illusory problem? Drug Alcohol Depend 88:156–162PubMedCentralPubMedCrossRefGoogle Scholar
  16. Kanayama G, Kean J, Hudson JI et al. (2013) Cognitive deficits in long-term anabolic-androgenic steroid users. Drug Alcohol Depend 130:208–214PubMedCentralPubMedCrossRefGoogle Scholar
  17. Kashkin KB, Kleber HD (1989) Hooked on hormones? An anabolic steroid addiction hypothesis. JAMA 262:3166–3170PubMedCrossRefGoogle Scholar
  18. Kouri EM, Pope HG Jr, Katz DL et al (1995) Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clin J Sport Med 5:223–228PubMedCrossRefGoogle Scholar
  19. Kutscher EC, Lund BC, Perry PJ (2002) Anabolic steroids: a review for the clinician. Sports Med 32:285–296PubMedCrossRefGoogle Scholar
  20. Lundholm L, Kall K, Wallin S et al (2010) Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug Alcohol Depend 111:222–226PubMedCrossRefGoogle Scholar
  21. Malone DA Jr, Dimeff RJ (1992) The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J Clin Psychiatry 53:130–132PubMedGoogle Scholar
  22. Melnik BC (2009) Androgen abuse in the community. Curr Opin Endocrinol Diabetes Obes 16:218–223PubMedCrossRefGoogle Scholar
  23. Nyberg F, Hallberg M (2012) Interactions between opioids and anabolic androgenic steroids: implications for the development of addictive behavior. Int Rev Neurobiol 102:189–206PubMedCrossRefGoogle Scholar
  24. Phillips KA, Didie ER, Feusner J et al (2008) Body dysmorphic disorder: treating an underrecognized disorder. Am J Psychiatry 165:1111–1118PubMedCentralPubMedCrossRefGoogle Scholar
  25. Pope HG, Katz DL (2003) Psychiatric effects of exogenous anabolic-androgenic steroids. In: Wolkowitz OM, Rothschild AJ (eds) Psychoneuroendocrinology: the scientific basis of clinical practice. American Psychiatric Press, Washington, DC, pp 331–358Google Scholar
  26. Pope HG, Kanayama G, Ionescu-Pioggia M et al (2004) Anabolic steroid users’ attitudes towards physicians. Addiction 99:1189–1194PubMedCrossRefGoogle Scholar
  27. Rohman L (2009) The relationship between anabolic androgenic steroids and muscle dysmorphia: a review. Eat Disord 17:187–199PubMedCrossRefGoogle Scholar
  28. Skarberg K, Nyberg F, Engstrom I (2009) Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur Addict Res 15:99–106PubMedCrossRefGoogle Scholar
  29. Tan RS, Scally MC (2009) Anabolic steroid-induced hypogonadism – towards a unified hypothesis of anabolic steroid action. Med Hypotheses 72:723–728PubMedCrossRefGoogle Scholar
  30. Wood RI (2008) Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol 29:490–506PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  1. 1.Biological Psychiatry Laboratory, Department of PsychiatryMcLean Hospital, Harvard Medical SchoolBelmontUSA

Personalised recommendations